|
|
|
Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) |
|
Rhythm Pharmaceuticals Inc
Officers & Directors
Christopher P. German Corporate Controller Jennifer L. Good Director Lynn A. Tetrault Director David P. Meeker, M.D. Chief Executive Officer, Director, Chairman of the Board Hunter Smith Chief Financial Officer Christophe R. Jean Director Stuart Arbuckle Director Camille L. Bedrosian, M.D. Director David W. J. McGirr Director Edward T. Mathers Lead Director ,
Rhythm Pharmaceuticals Inc currently has 414 employees.
News about Rhythm Pharmaceuticals Inc Key Personnel |
Rhythm Pharmaceuticals: Navigating Growth Amidst Challenges and BreakthroughsRhythm Pharmaceuticals, Inc. has made significant strides and faced notable challenges in 2024, as articulated in their preliminary financial announcements and recent FDA developments. This article aims to dissect the key facts surrounding the company s performance, product approvals, and its future outlook. Financial Performance and Product RevenuesIn its preliminary unaudited financial results, Rhythm Pharmaceuticals reported net revenues of approximately $42 million for the fourth quarter and around $130 million for the entire year of 2024 from global sales of its flagship product, IMCIVREE (setmelanotide). While these figures ...
|
Rhythm Pharmaceuticals’ New Milestone: A Beacon of Hope or a Signal of Trouble?BOSTON, Dec. 20, 2024 – In a significant move that underscores the urgency in treating rare genetic disorders, Rhythm Pharmaceuticals, Inc. has officially announced FDA approval for its groundbreaking drug, IMCIVREE (setmelanotide), for patients as young as two years old. This approval extends the drug s indication to pediatric patients afflicted by syndromic or monogenic obesity, particularly conditions such as Bardet-Biedl syndrome (BBS) and genetically confirmed deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), and leptin receptor (LEPR) deficiency.IMCIVREE operates as a me...
|
Rhythm Pharmaceuticals Grants Employment Inducement Equity to Drive Growth a...
|
Rhythm Pharmaceuticals, a leading biopharmaceutical company dedicated to improving the lives of patients and families facing rare neuroendocrine diseases, recently announced the issuance of employment inducement grants to four highly skilled individuals. These grants, which comprise inducement stock options and restricted stock units (RSUs), signify the company s commitment to attracting top talent and fostering a culture of innovation. By offering these valuable incentives, Rhythm Pharmaceuticals aims to drive its growth trajectory and fulfill its mission of transforming the lives of patients affected by rare melanocortin-4 receptor pathway diseases.
On January 9, 2023, Rhythm Pharmaceuticals Comp...
|
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
